Sodium glucose cotransporter 2 inhibitors are associated with renal stabilization in heart transplantation

Raven, Lisa M. and Greenfield, Jerry R. and Jabbour, Andrew and Macdonald, Peter S. and Muir, Christopher A. (2025) Sodium glucose cotransporter 2 inhibitors are associated with renal stabilization in heart transplantation. JHLT Open, 8. p. 100255. ISSN 29501334

Full text not available from this repository.
Link to published document: https://doi.org/10.1016/j.jhlto.2025.100255

Abstract

Sodium glucose cotransporter 2 inhibitors (SGLT2i) are standard of care for type 2 diabetes mellitus, heart failure, and chronic kidney disease (CKD). Heart transplant (HTx) recipients are at increased risk of diabetes and CKD, and both are independently associated with increased mortality. In a retrospective analysis of 104 HTx recipients with diabetes (23 exposed to SGLT2i, 81 not exposed), SGLT2i treatment was associated with stable renal function at 3 years post-HTx, measured by estimated glomerular filtration rate change from baseline (median change of 0 ml/min/1.73 m(2) (interquartile range [IQR] -13 to +11)), compared to a change of -15 ml/min/1.73 m(2) (IQR -27 to +1) in patients not exposed to SGLT2i (p = 0.02). There was no significant difference in survival by SGLT2i exposure, adjusted for diabetes type and baseline creatinine (hazard ratio 0.34, confidence intervals 0.11-1.06, p = 0.06). Further investigation of SGLT2i in HTx recipients, particularly focusing on renal outcomes, is required.

Item Type: Article
Subjects: R Medicine > R Medicine (General)
Depositing User: Repository Administrator
Date Deposited: 05 May 2025 06:46
Last Modified: 05 May 2025 06:46
URI: https://eprints.victorchang.edu.au/id/eprint/1695

Actions (login required)

View Item View Item